REGENXBIO - RGNX Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued twelve-month price objectives for REGENXBIO's stock. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they anticipate the company's stock price to reach $41.43 in the next year. This suggests a possible upside of 74.4% from the stock's current price.
View analysts price targets for RGNX or view top-rated stocks among Wall Street analysts.

REGENXBIO's stock was trading at $22.68 at the beginning of the year. Since then, RGNX stock has increased by 4.7% and is now trading at $23.75.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RGNX earnings forecast.

REGENXBIO Inc. (NASDAQ:RGNX) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($1.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.50. The biotechnology company had revenue of $30.77 million for the quarter, compared to analysts' expectations of $49.35 million. REGENXBIO had a net margin of 15.34% and a trailing twelve-month return on equity of 12.22%. During the same period in the previous year, the company earned $0.23 EPS.

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

REGENXBIO's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.24%), Monarch Partners Asset Management LLC (0.17%), Harbor Capital Advisors Inc. (0.06%), SummerHaven Investment Management LLC (0.06%), Essex Investment Management Co. LLC (0.06%) and Yousif Capital Management LLC (0.06%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends.

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGNX stock can currently be purchased for approximately $23.75.

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $1.03 billion and generates $480.03 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $1.55 on an earnings per share basis.

The company employs 372 workers across the globe.

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.